Indecainide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318059

CAS#: 74517-78-5

Description: Indecainide is a rarely used antidysrhythmic. Indecainide has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of antiarrhythmic agents; it has electrophysiologic effects characteristic of the IC class of antiarrhythmics.

Chemical Structure

img
Indecainide
CAS# 74517-78-5
Instruction

Theoretical Analysis

MedKoo Cat#: 318059
Name: Indecainide
CAS#: 74517-78-5
Chemical Formula: C20H24N2O
Exact Mass: 308.19
Molecular Weight: 308.417
Elemental Analysis: C, 77.89; H, 7.84; N, 9.08; O, 5.19

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Ricainid, Indecainida, Indecainidum, Decabid, Ricainide

IUPAC/Chemical Name: 9-[3-(propan-2-ylamino)propyl]fluorene-9-carboxamide

InChi Key: UCEWGESNIULAGX-UHFFFAOYSA-N

InChi Code: InChI=1S/C20H24N2O/c1-14(2)22-13-7-12-20(19(21)23)17-10-5-3-8-15(17)16-9-4-6-11-18(16)20/h3-6,8-11,14,22H,7,12-13H2,1-2H3,(H2,21,23)

SMILES Code: O=C(C1(CCCNC(C)C)C2=C(C3=C1C=CC=C3)C=CC=C2)N

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 308.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Pratt CM, Francis MJ, Seals AA, Zoghbi W, Young JB. Antiarrhythmic and hemodynamic evaluation of indecainide and procainamide in nonsustained ventricular tachycardia. Am J Cardiol. 1990 Jul 1;66(1):68-74. PubMed PMID: 2193498.

2: Macina G, Turitto G, Stavens C, Fontaine J, Hariman R, Ursell S, el-Sherif N. Antiarrhythmic effects of oral indecainide in patients with ventricular tachyarrhythmias. Clin Cardiol. 1987 Jun;10(6):357-61. PubMed PMID: 3594958.

3: Nestico PF, Morganroth J, Horowitz LN, Mulhern C. Efficacy of oral and intravenous indecainide in ventricular arrhythmias. Am J Cardiol. 1987 Jun 1;59(15):1332-6. PubMed PMID: 3296725.

4: Dennis PD, Vaughan Williams EM. The effects of indecainide, a new antidysrhythmic drug, on nodal tissues in the isolated rabbit heart. J Cardiovasc Pharmacol. 1986 Jan-Feb;8(1):1-5. PubMed PMID: 2419671.

5: Horowitz LN, Spielman SR, Webb CR, Morganroth J, Greenspan AM. The clinical electrophysiology of intravenous indecainide. Am Heart J. 1985 Oct;110(4):784-8. PubMed PMID: 4050649.

6: Dennis PD, Vaughan Williams EM. Effects on rabbit cardiac potentials of aprindine and indecainide, a new antiarrhythmic agent, in normoxia and hypoxia. Br J Pharmacol. 1985 May;85(1):11-9. PubMed PMID: 4027460; PubMed Central PMCID: PMC1916771.

7: Lindstrom TD, Lacefield WB, Whitaker GW. Metabolism of the antiarrhythmic agent, indecainide, in rats, dogs, and monkeys. Drug Metab Dispos. 1984 Nov-Dec;12(6):691-7. PubMed PMID: 6150817.

8: Giardina EV, Saroff AL, Schneider M. Effect of indecainide in patients with left ventricular dysfunction. Clin Pharmacol Ther. 1990 Nov;48(5):582-9. PubMed PMID: 2225716.

9: Holland DR, Lacefield WB, Gonzales CR, Johnston SR, Turk JA. Indecainide: effects on arrhythmias, electrophysiology, and cardiovascular dynamics. J Cardiovasc Pharmacol. 1989 Sep;14(3):454-61. PubMed PMID: 2476626.

10: Salerno DM, Krejci J, Granrud G, Hodges M. Indecainide for treatment of ventricular ectopic depolarizations: efficacy, pharmacokinetics, hemodynamic effects and safety. J Am Coll Cardiol. 1988 Apr;11(4):843-50. PubMed PMID: 3351153.

11: Podrid PJ, Hohnloser S, Lown B. Noninvasive evaluation of indecainide for serious ventricular tachyarrhythmia. Am J Cardiol. 1988 Apr 1;61(10):764-9. PubMed PMID: 2451415.

12: Sandusky GE, Usher RW, Tamura RN. Chronic dietary oncogenicity studies of indecainide in rats and mice. Fundam Appl Toxicol. 1987 Oct;9(3):436-47. PubMed PMID: 3692003.

13: Giardina EG, Zaim S, Saroff AL, Kirschenbaum M. Indecainide compared with quinidine for chronic stable ventricular arrhythmias secondary to coronary artery disease or to cardiomyopathy. Am J Cardiol. 1987 Sep 1;60(7):584-9. PubMed PMID: 2442993.

14: Miura DS, Wynn J, Keefe D, Laux B, Somberg JC. Antiarrhythmic effects of indecainide in a drug-resistant population with ventricular tachycardia at programmed electrical stimulation. Am Heart J. 1987 Jan;113(1):65-9. PubMed PMID: 3799443.

15: Sandusky GE Jr, Meyers DB. Toxicology of indecainide hydrochloride after intravenous administration to rats and dogs. Toxicol Lett. 1985 Aug;26(2-3):107-10. PubMed PMID: 4035704.

16: Farid KZ, Fasola AF, Nash JF. Liquid chromatographic determination of indecainide, a new antiarrhythmic drug, and its major metabolite, desisopropyl indecainide, in biological samples. J Chromatogr. 1985 Feb 8;337(2):329-40. PubMed PMID: 3988863.

17: Sandusky GE Jr, Meyers DB. Toxicology of indecainide hydrochloride in mice, rats, and dogs. Fundam Appl Toxicol. 1985 Feb;5(1):175-81. PubMed PMID: 3921422.

18: Lindstrom TD, Whitaker GW. The pharmacokinetics of indecainide in mice, rats, dogs, and monkeys. Drug Metab Dispos. 1984 Nov-Dec;12(6):683-90. PubMed PMID: 6150816.

19: Steinberg MI, Wiest SA. Electrophysiological studies of indecainide hydrochloride, a new antiarrhythmic agent, in canine cardiac tissues. J Cardiovasc Pharmacol. 1984 Jul-Aug;6(4):614-21. PubMed PMID: 6206315.